ArticleActa endocrinologica (Bucharest, Romania : 2005)
A RARE DETERMINATION OF SMALL LYMPHOCYTIC LYMPHOMA ASSOCIATED WITH UNFAVORABLE EVOLUTION AND REVIEW OF THE LITERATURE.
Article in Acta endocrinologica (Bucharest, Romania : 2005). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small lymphocytic lymphoma (SLL) is an indolent lymphoma. Hypercalcemia is rarely associated with this type of lymphoma and was reported as a Richter`s transformation sign of SLL in the literature. We report a case of a 64-year-old man, with many comorbidities, including cardiac and renal pathologies, known with hepatitis B. Small lymphocytic B lymphoma with genetic risk factors, such as TP53, 17p and unmutated IGHV was diagnosed by laterocervical node biopsy. During chemotherapy, the patient initially presented sciatic pain, leading to the suspicion of a new associated malignancy, but the lumbar MRI excluded osteolysis. A few weeks later, the patient presented with neurological symptoms and dangerous hypercalcemia and high levels of iPTH were discovered. Parathyroid determination was discovered and the second line therapy with Venetoclax- Rituximab was chosen, but unfavorable evolution was noted, with activated macrophage syndrome, disseminated intravascular coagulation and multiple organ dysfunction syndrome. The genetic risk factors and the presence of hypercalcemia are markers of negative prognosis and unfavorable evolution of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.